Comparison

Draflazine European Partner

Item no. HY-106841-25mg
Manufacturer MedChem Express
CASRN 120770-34-5
Amount 25 mg
Quantity options 100 mg 10 mg 1 ea 25 mg 50 mg 5 mg
Category
Type Molecules
Specific against other
Purity 99.06
Citations [1]Maes SS, et al. Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigs. J Pain Res. 2012;5:391-400.
Smiles O=C(NC1=C(Cl)C=C(N)C=C1Cl)CN2C(C(N)=O)CN(CCCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias R-75231,R88021
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
Adenosine Receptor; Nucleoside Transporters
Shipping Temperature
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight
604.52
Product Description
Draflazine (R-75231) is a ENT1 inhibitor. Draflazine (R-75231) completely reverses the hypersensitivity in the complete Freund’s adjuvant (CFA) model of mechanical hyperalgesia and the carrageenan inflammation model of thermal and mechanical hyperalgesia[1].
Manufacturer - Research Area
Inflammation/Immunology
Solubility
DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway
GPCR/G Protein; Membrane Transporter/Ion Channel
Clinical information
Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close